450 related articles for article (PubMed ID: 18389279)
1. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.
Proesmans M; Vermeulen F; De Boeck K
Eur J Pediatr; 2008 Aug; 167(8):839-49. PubMed ID: 18389279
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators.
Perrem L; Ratjen F
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S46-S55. PubMed ID: 31715088
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.
Kreindler JL
Pharmacol Ther; 2010 Feb; 125(2):219-29. PubMed ID: 19903491
[TBL] [Abstract][Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
7. New treatments targeting the basic defects in cystic fibrosis.
Fajac I; Wainwright CE
Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
[TBL] [Abstract][Full Text] [Related]
8. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
9. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
10. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[TBL] [Abstract][Full Text] [Related]
11. [CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
Becq F
Arch Pediatr; 2003 Sep; 10 Suppl 2():325s-332s. PubMed ID: 14671929
[TBL] [Abstract][Full Text] [Related]
12. [Physiopathology of cystic fibrosis lung disease].
Chinet T
Rev Mal Respir; 1999 Jun; 16(3):339-45. PubMed ID: 10472642
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.
Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M
Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
16. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
17. Role of CFTR in airway disease.
Pilewski JM; Frizzell RA
Physiol Rev; 1999 Jan; 79(1 Suppl):S215-55. PubMed ID: 9922383
[TBL] [Abstract][Full Text] [Related]
18. [Evidence-based treatment of cystic fibrosis].
Ringshausen FC; Hellmuth T; Dittrich AM
Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
[TBL] [Abstract][Full Text] [Related]
19. Cystic Fibrosis: Pathophysiology of Lung Disease.
Bergeron C; Cantin AM
Semin Respir Crit Care Med; 2019 Dec; 40(6):715-726. PubMed ID: 31659725
[TBL] [Abstract][Full Text] [Related]
20. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
